R&D News | pharmaphorum

News

Phase 3 setbacks mar Eisai, Merck’s cancer alliance

Two late-stage trials combining Merck & Co’s cancer immunotherapy Keytruda with Eisai’s targeted cancer drug Lenvima have generated disappointing results in hard-to-tr

News

Merck gets stuck on Proxygen’s molecular glue degraders

Proxygen has added another big pharma company to its list of partners, with Merck & Co the latest to be snared by its molecular glue degrader technology.

News

Beckley Psytech CEO Cosmo Feilding Mellen and chair of scientific advisory board Lady Amanda Feilding

Could psychedelic drugs treat alcohol use disorder?

A new clinical trial is hoping to show that treatment with a psychedelic drug in development at UK startup Beckley Psytech could help people battling alcohol use disorder

News

BenevolentAI lead atopic dermatitis drug misses the mark

BenevolentAI has reported disappointing results in a phase 2 trial of lead drug BEN-2293 in atopic dermatitis (AD), as the drug was unable to show the hoped-for effect on

News

Cure Ventures launches with $350m early-stage biotech fund

There’s a new biotech venture capital fund on the scene, following the launch today of Cure Ventures with $350 million in capital commitments and a pledge to help start-up

News

Okyo Pharma abandons UK listing in favour of Nasdaq

Okyo Pharma has decided to delist its shares from the London Stock Exchange and list them on the Nasdaq in New York, blaming “negligible” trading that doesn’t justify the

Phase 3 setbacks mar Eisai, Merck’s cancer alliance

Merck gets stuck on Proxygen’s molecular glue degraders

Could psychedelic drugs treat alcohol use disorder?

BenevolentAI lead atopic dermatitis drug misses the mark

Cure Ventures launches with $350m early-stage biotech fund

Okyo Pharma abandons UK listing in favour of Nasdaq

Pharvaris plans filings for HAE drug after pivotal trial win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks